亲和体分子探针与18F-FDG在PET/CT检测HER2阳性乳腺癌中的比较
前瞻性研究纳入42例HER2阳性乳腺癌患者,均行Al18F-NOTA-HER2-BCH与18F-FDG PET/CT。亲和体探针检出原发灶及淋巴结、骨、肝转移灶数量均多于18F-FDG,相应SUVmax与TBR更高;胸壁及肺转移灶两者SUVmax与TBR无显著差异。
要点
- Al18F-NOTA-HER2-BCH PET/CT检出原发灶26个,18F-FDG检出21个。
- 亲和体探针检出淋巴结转移170个、骨转移92个、肝转移55个,均多于18F-FDG的130、66、27个。
- 原发灶及淋巴结、骨、肝转移灶SUVmax和TBR在亲和体探针图像上均高于18F-FDG图像。
核心结论
- 亲和体探针Al18F-NOTA-HER2-BCH PET/CT较18F-FDG PET/CT可检出更多原发灶及淋巴结、骨、肝转移灶。
研究设计与样本
- 前瞻性研究,2020年6月至2023年7月纳入42例HER2阳性乳腺癌患者(平均年龄56.3岁±10.1[SD],41例女性),均行Al18F-NOTA-HER2-BCH与18F-FDG PET/CT,以病理评估(免疫组化3+或2+且FISH显示HER2扩增)确认HER2阳性。
关键影像表现/征象
- Al18F-NOTA-HER2-BCH PET/CT检出42例(100%)患者的肿瘤,18F-FDG PET/CT检出40例(95.2%)。
- 仅Al18F-NOTA-HER2-BCH显像:21例中2例原发灶、21例中4例淋巴结转移、15例中4例骨转移、9例中3例肝转移。
- 仅18F-FDG显像:9例中1例肺转移。
诊断标准与关键数值
- HER2阳性判定:免疫组化3+,或2+且荧光原位杂交显示HER2扩增。
- 两名独立阅片者视觉评估示踪剂摄取,并以SUVmax和靶/本底比(TBR)定量。
- 原发灶及淋巴结、骨、肝转移灶中位SUVmax:Al18F-NOTA-HER2-BCH为10.4-13.5 vs 18F-FDG为3.4-6.2(P值范围<.001至.02)。
- 原发灶及淋巴结、骨、肝转移灶中位TBR:Al18F-NOTA-HER2-BCH为2.7-17.6 vs 18F-FDG为1.2-7.8(P值范围<.001至.001)。
- 胸壁或肺转移灶SUVmax与TBR在两种示踪剂间无差异证据(P值范围.06至.53)。
临床应用与阅片要点
- 亲和体探针Al18F-NOTA-HER2-BCH PET/CT可检出更多HER2阳性原发灶及淋巴结、骨、肝转移灶。
- 胸壁或肺转移灶的SUVmax与TBR在Al18F-NOTA-HER2-BCH与18F-FDG间无差异证据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Human epidermal growth factor receptor 2 (HER2) affibody-based tracers could be an alternative to nonspecific radiotracers for noninvasive detection of HER2 expression in breast cancer lesions at PET/CT. Purpose To compare an affibody-based tracer, Al18F-NOTA-HER2-BCH, and fluorine 18 (18F) fluorodeoxyglucose (FDG) for detecting HER2-positive breast cancer lesions on PET/CT images. Materials and Methods In this prospective study conducted from June 2020 to July 2023, participants with HER2-positive breast cancer underwent both Al18F-NOTA-HER2-BCH and 18F-FDG PET/CT. HER2 positivity was confirmed with pathologic assessment (immunohistochemistry test results of 3+, or 2+ followed by fluorescence in situ hybridization, indicated HER2 amplification). Two independent readers visually assessed the uptake of tracers on images. Lesion uptake was quantified using the maximum standardized uptake value (SUVmax) and target to background ratio (TBR) and compared using a general linear mixed model. Results A total of 42 participants (mean age, 56.3 years ± 10.1 [SD]; 41 female) with HER2-positive breast cancer were included; 42 (100%) had tumors that were detected with Al18F-NOTA-HER2-BCH PET/CT and 40 (95.2%) had tumors detected with 18F-FDG PET/CT. Primary tumors in two of 21 participants, lymph node metastases in four of 21 participants, bone metastases in four of 15 participants, and liver metastases in three of nine participants were visualized only with Al18F-NOTA-HER2-BCH. Lung metastasis in one of nine participants was visualized only with 18F-FDG. Al18F-NOTA-HER2-BCH enabled depiction of more suspected HER2-positive primary tumors (26 vs 21) and lymph node (170 vs 130), bone (92 vs 66), and liver (55 vs 27) metastases than 18F-FDG. The SUVmax and TBR values of primary tumors and lymph node, bone, and liver metastases were all higher on Al18F-NOTA-HER2-BCH images than on 18F-FDG images (median SUVmax range, 10.4-13.5 vs 3.4-6.2; P value range, <.001 to .02; median TBR range, 2.7-17.6 vs 1.2-7.8; P value range, <.001 to .001). No evidence of differences in the SUVmax and TBR for chest wall or lung metastases was observed between Al18F-NOTA-HER2-BCH and 18F-FDG (P value range, .06 to .53). Conclusion PET/CT with the affibody-based tracer Al18F-NOTA-HER2-BCH enabled detection of more primary lesions and lymph node, bone, and liver metastases than PET/CT using 18F-FDG. ClinicalTrials.gov Identifier: NCT04547309 © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Ulaner in this issue.
引用
- Guo X, Zhou N, Liu J, et al. Comparison of an Affibody-based Molecular Probe and 18F-FDG for Detecting HER2-Positive Breast Cancer at PET/CT. Radiology. 2024. PMID: 38888484. doi:10.1148/radiol.232209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。